Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound. The pharma company ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Buy now, pay later is a common tool to help shoppers purchase things like consumer electronics and furniture. But can this short-term financing method help people pay for expensive weight-loss drugs?

Amgen could tap into more growth opportunities by entering ... Eli Lilly's medicines, such as Mounjaro and Zepbound, are racking up incredible sales, and they are still on an upward path. Further, ...

As the popularity of Ozempic, Victoza, Wegovy and other GLP-1 agonists have continued to increase, ... More so have restrictions on insurance coverage for many of them. (Photo by: Michael Siluk ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. Historically, the California-based pharma has remained ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...